Gene therapy for ocular disorders
US11879133B2 · kind B2 · utility
0Cited by
23References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 24, 2018 |
| Grant date | Jan 23, 2024 |
| Priority date | — |
| Expiry date | Jan 3, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2800/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods are provided for treating ocular neuropathy in a subject. In one aspect, a recombinant adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding NRF2. In another aspect, a recombinant adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding SIRT1. In desired embodiments, the subject is human, cat, dog, sheep, or non-human primate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.